Valuation: Valerio Therapeutics

Market Cap 228M 261M 211M 193M 366M 25.13B 373M 2.51B 988M 12.27B 980M 958M 42.37B P/E 2024
-0.47x
P/E 2025 -6.9x
Enterprise Value 235M 269M 218M 200M 378M 25.93B 384M 2.59B 1.02B 12.66B 1.01B 989M 43.72B EV / Sales 2024
15x
EV / Sales 2025 29x
Free-Float
64.77%
Yield 2024 *
-
Yield 2025 -
1 day+30.78%
1 week+32.67%
Current month+178.32%
1 month+207.73%
3 months+342.22%
6 months+323.40%
Current year+332.61%
1 week 0.37
Extreme 0.3705
0.6
1 month 0.19
Extreme 0.192
0.6
Current year 0.1
Extreme 0.1025
0.6
1 year 0.05
Extreme 0.054
0.6
3 years 0.04
Extreme 0.0401
0.6
5 years 0.04
Extreme 0.0401
0.75
10 years 0.04
Extreme 0.0401
5.46
Manager TitleAgeSince
Chief Executive Officer - 2026-06-30
Chief Executive Officer 51 2022-04-05
Director of Finance/CFO - 2022-02-28
Director TitleAgeSince
Director/Board Member 63 2011-06-28
Chairman 43 2024-11-12
Chairman 66 -
Date Insider Type Main position Quantity % Market Cap.
4/22/21 Buy 4,225,352 4.6244%
11/4/20 Buy 333 0.0004%
11/4/20 Buy 22,870 0.0292%
Change 5-day change 1-year change 3-year change Capi.($)
+30.78%+32.67%+1,005.56%+145.68% 261M
+1.79%-3.34%+48.93%+163.06% 1,031B
+1.04%-3.59%+51.59%+57.03% 595B
+3.18%+0.87%+32.27%+86.96% 431B
+0.42%-1.16%+29.43%+23.64% 326B
+1.03%-0.84%+29.58%+45.15% 277B
+0.49%-5.44%+21.00%+23.80% 263B
+1.59%+4.89%-22.56%-37.35% 224B
+2.87%+1.26%+23.13%+61.60% 193B
+1.38%-1.11%+21.39%+72.10% 164B
Average +4.39%-3.38%+124.03%+64.17% 350.46B
Weighted average by Cap. +1.52%-4.31%+34.69%+80.31%

Financials

2024 2025
Net sales 1.79M 2.05M 1.66M 1.52M 2.88M 198M 2.93M 19.77M 7.77M 96.52M 7.7M 7.53M 333M 2.57M 2.94M 2.38M 2.18M 4.13M 284M 4.2M 28.38M 11.15M 139M 11.05M 10.81M 478M
Net income -23.93M -27.38M -22.13M -20.31M -38.44M -2.64B -39.1M -264M -104M -1.29B -103M -101M -4.45B -4.9M -5.6M -4.53M -4.16M -7.87M -540M -8M -54.02M -21.22M -264M -21.04M -20.58M -910M
Net Debt 15.38M 17.6M 14.23M 13.06M 24.71M 1.7B 25.14M 170M 66.65M 828M 66.09M 64.64M 2.86B 7.26M 8.31M 6.71M 6.16M 11.66M 800M 11.86M 80.07M 31.45M 391M 31.19M 30.51M 1.35B
Logo Valerio Therapeutics
Valerio Therapeutics is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled mechanisms of action in the highly sought-after field of DNA damage response (DDR). The company focuses on the development of innovative first-in-class or disruptive compounds (in-house, acquired or licensed) from translational research to human clinical proof of concept. Valerio Therapeutics has platON®, its proprietary decoy oligonucleotide chemistry platform, and V-Body, the platform for generating single-domain therapeutic antibodies. These two proprietary platforms are dedicated to the generation of innovative new compounds to enrich the company's product portfolio. AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company, and V-Body, the platform for generating single-domain therapeutic antibodies. These two proprietary platforms are dedicated. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing VIO-01 (previously OX425), a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. The clinical development of VIO-01 was stopped in early 2025 in order to redirect research and development efforts towards next-generation drug candidates based on the PlatON and VBody platforms.
Employees
25
Date Price Change Volume
26-07-16 0.5970 +30.78% 7,704,248
26-07-15 €0.4565 +6.41% 2,457,111
26-07-14 €0.4290 +7.25% 1,247,307
26-07-13 €0.4000 -11.11% 782,718
26-07-10 €0.4500 0.00% 1,155,371
  1. Stock Market
  2. Stocks
  3. ALVIO Stock